Skip to content
DataLookout
Menu

LEGACYNCT01848561

A Long-Term Registry of Humira® (Adalimumab) in Patients With Moderately to Severely Active Ulcerative Colitis (UC)

StatusCompleted
PhaseNot specified
SponsorAbbVie
Primary completion
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 36 versions: 34 with changes below, 2 re-verified with no change. See every version on ClinicalTrials.gov ↗

  1. Notable Eligibility criteria expanded, about 7 words
    • Trial completed
    • Primary completion date changed from estimate of Jun 2028 to Sep 30, 2026
    • Study sites revised (512)
  2. Notable Primary and study completion dates: Jun 24, 2030 to Jun 2028
    • Study sites: 511 to 512
    v35
  3. Minor Study sites: 510 to 511v34
  4. Minor Study sites: 513 to 510v33
  5. Notable Primary completion date: Apr 6, 2027 to Jun 24, 2030
    • Study sites revised (513)
    v32
Show 28 earlier versionsHide 28 earlier versions
  1. Notable Primary completion date: Jun 24, 2030 to Apr 6, 2027
    • Enrollment target: 5573 to 8250
    • Study sites: 514 to 513
    v31
  2. Notable Primary and study completion dates: Apr 6, 2027 to Jun 24, 2030
    • Trial status: Recruiting to Active, Not Recruiting
    • Enrollment target: estimated 8250 to confirmed 5573
    • Study sites: 515 to 514
    v30
  3. Notable Enrollment target: 5450 to 8250
    • Study sites revised (515)
    v29
  4. Notable Enrollment target: 8250 to 5450
    • Study sites: 475 to 515
    v28
  5. Minor Study sites: 468 to 475v27
  6. Minor Study sites: 467 to 468v26
  7. Notable Eligibility criteria revised
    • Study sites: 460 to 467
    v25
  8. Notable Eligibility criteria revised
    • Study sites: 468 to 460
    v24
  9. Minor Study sites: 601 to 468v22
  10. Minor Primary and study completion dates: Apr 26, 2027 to Apr 6, 2027v21
  11. Minor Study sites: 599 to 601v19
  12. Minor Study sites: 587 to 599
    • Primary and study completion dates: Apr 2027 to Apr 26, 2027
    • Start date: Apr 2013 to Apr 29, 2013
    v18
  13. Minor Study sites: 585 to 587v17
  14. Minor Study sites: 568 to 585v16
  15. Minor Study sites: 560 to 568v15
  16. Minor Study sites: 555 to 560v14
  17. Minor Study sites: 553 to 555v13
  18. Notable Eligibility criteria expanded, about 4 words
    • Study sites: 538 to 553
    v12
  19. Minor Study sites: 502 to 538v11
  20. Minor Study sites: 459 to 502v10
  21. Minor Study sites: 444 to 459v9
  22. Minor Study sites: 416 to 444v8
  23. Minor Study sites: 404 to 416v7
  24. Notable Eligibility criteria shortened, about 21 words
    • Study sites: 290 to 404
    • Secondary endpoints: details revised at 1 of 1 entry
    v6
  25. Minor Study sites: 241 to 290
    • Interventions: Adalimumab (Biological), Immunomodulatory therapy (Drug) to not stated
    v5
  26. Minor Study sites: 29 to 241v4
  27. Minor Study sites: 11 to 29
    • Start date: May 2013 to Apr 2013
    v3
  28. Minor Study sites: 1 to 11
    • Start date: Apr 2013 to May 2013
    v2
  1. Study First Submitted
  • Notable: the plan changed
  • Minor: routine updates

Endpoints

Primary

Evaluation of long term safety of Adalimumab in patients with moderately to severely active UC
Timeframe: 10 years observational period

Secondary (1)

Evaluation of long term effectiveness of Adalimumab in patients with moderately to severely active UC who have had an inadequate response to conventional therapy

Arms and interventions

Immunomodulatory Therapy

Patients who are being prescribed and treated with Immunomodulatory Therapy

Adalimumab (Humira) Treatment

Patients who are prescribed and treated with Adalimumab

Sites

512 sites in 21 countries

United States 170, Spain 69, Germany 63, Italy 29, United Kingdom 28, France 27, Canada 21, Belgium 15, Australia 14, Mexico 13, Greece 11, Israel 10, Netherlands 8, Ireland 7, Sweden 7, Austria 5, Croatia 5, Denmark 4, Puerto Rico 4, New Zealand 1, Norway 1